Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: Effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model

Vaccine

Volumn 26, Issue 51, 2008, Pages 6555-6563

  Hagenaars, Niels ^a   Mastrobattista, Enrico ^a   Glansbeek, Harrie ^b   Heldens, Jacco ^b   van den Bosch, Han ^b   Schijns, Virgil ^b   Betbeder, Didier ^c,d   Vromans, Herman ^a,e   Jiskoot, Wim ^f  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Nobilon International BV   (Netherlands)

^c France Institut Pasteur de Lille   (France)

^d UNIVERSITÉ D'ARTOIS   (France)

^e Organon part of Schering Plough ^*  (Netherlands)

^f LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Influenza vaccination; Nasal vaccination; Split vaccine; Subunit vaccine; Virosomes; Whole inactivated virus

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; VIROSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG FORMULATION; FEMALE; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; IMMUNITY, MUCOSAL; IMMUNIZATION; IMMUNOGLOBULIN A, SECRETORY; IMMUNOGLOBULIN G; INFLUENZA A VIRUS; INFLUENZA VACCINES; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE INFECTIONS; VACCINES, INACTIVATED; VACCINES, SUBUNIT; VIROSOMES;

EID: 58149197779     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.09.057     Document Type: Article

References (54)

1. de Jong J.C., Claas E.C., Osterhaus A.D., Webster R.G., and Lim W.L. A pandemic warning?. Nature 389 6651 (1997) 554
2. Details of new influenza research projects announced today. Press release. Brussels: European Union; 2007 11 September 2007. Report No.: MEMO/07/348.
3. Morales A., Arias Salazar J., Salazar Y., Garcia A., Arnoux S., Arancibia A., et al. A randomized controlled trial comparing split and subunit influenza vaccines in adults in Colombia. Medicina (B Aires) 63 3 (2003) 197-204
4. Beyer W.E.P., Palache A.M., and Osterhaus A.D.M.E. Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines-a review and meta-analysis of the literature. Clin Drug Invest 15 1 (1998) 1-12
5. Ruf B.R., Colberg K., Frick M., and Preusche A. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly. Infection 32 4 (2004) 191-198
6. Zei T., Neri M., and Iorio A.M. Immunogenicity of trivalent subunit and split influenza vaccines (1989-90 winter season) in volunteers of different groups of age. Vaccine 9 9 (1991) 613-617
7. de Bruijn I.A., Nauta J., Cramer W.C., Gerez L., and Palache A.M. Clinical experience with inactivated, virosomal influenza vaccine. Vaccine 23 Suppl. 1 (2005) S39-49
8. Samdal H.H., Bakke H., Oftung F., Holst J., Haugen I.L., Korsvold G.E., et al. A non-living nasal influenza vaccine can induce major humoral and cellular immune responses in humans without the need for adjuvants. Hum Vaccin 1 2 (2005) 85-90
9. Hovden A.O., Cox R.J., and Haaheim L.R. Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice. Scand J Immunol 62 1 (2005) 36-44
10. Gross P.A., Ennis F.A., Gaerlan P.F., Denson L.J., Denning C.R., and Schiffman D. A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children. J Infect Dis 136 5 (1977) 623-632
11. Gwaltney J.M., DeSanctis A.N., Metzgar D.P., and Hendley J.O. Systemic reactions to influenza B vaccine. Am J Epidemiol 105 3 (1977) 252-260
12. Jefferson T.O., Rivetti D., Di Pietrantonj C., Rivetti A., and Demicheli V. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2 (2007) CD001269
13. Palache A.M., Scheepers H.S., de Regt V., van Ewijk P., Baljet M., Brands R., et al. Safety, reactogenicity and immunogenicity of Madin Darby Canine Kidney cell-derived inactivated influenza subunit vaccine. A meta-analysis of clinical studies. Dev Biol Stand 98 (1999) 115-125 discussion 33-34
14. Halperin S.A., Smith B., Mabrouk T., Germain M., Trepanier P., Hassell T., et al. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine 20 7/8 (2002) 1240-1247
15. Slütter B., Hagenaars N., and Jiskoot W. Rational design of nasal vaccines. J Drug Target 16 1 (2008) 1-17
16. Renegar K.B., and Small Jr. P.A. Passive transfer of local immunity to influenza virus infection by IgA antibody. J Immunol 146 6 (1991) 1972-1978
17. Belshe R.B., Mendelman P.M., Treanor J., King J., Gruber W.C., Piedra P., et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 338 20 (1998) 1405-1412
18. Ambrose C.S., Walker R.E., and Connor E.M. Live attenuated influenza vaccine in children. Semin Pediatr Infect Dis 17 4 (2006) 206-212
19. Takada A., Matsushita S., Ninomiya A., Kawaoka Y., and Kida H. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine 21 23 (2003) 3212-3218
20. Minne A., Jaworska J., Gerhold K., Ahrens B., Avagyan A., Vanbever R., et al. Intranasal delivery of whole influenza vaccine prevents subsequent allergen-induced sensitization and airway hyper-reactivity in mice. Clin Exp Allergy 37 8 (2007) 1250-1258
21. Barry D.W., Staton E., and Mayner R.E. Inactivated influenza vaccine efficacy: diminished antigenicity of split-product vaccines in mice. Infect Immun 10 6 (1974) 1329-1336
22. Ben-Yehuda A., Joseph A., Zeira E., Even-Chen S., Louria-Hayon I., Babai I., et al. Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults. J Med Virol 69 4 (2003) 560-567
23. Bright R.A., Carter D.M., Daniluk S., Toapanta F.R., Ahmad A., Gavrilov V., et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 25 19 (2007) 3871-3878
24. Greenbaum E., Furst A., Kiderman A., Stewart B., Levy R., Schlesinger M., et al. Mucosal [SIgA] and serum [IgG] immunologic responses in the community after a single intra-nasal immunization with a new inactivated trivalent influenza vaccine. Vaccine 20 7-8 (2002) 1232-1239
25. Stegmann T., Morselt H.W., Booy F.P., van Breemen J.F., Scherphof G., and Wilschut J. Functional reconstitution of influenza virus envelopes. Embo J 6 9 (1987) 2651-2659
26. Chaloupka I., Schuler A., Marschall M., and Meier-Ewert H. Comparative analysis of six European influenza vaccines. Eur J Clin Microbiol Infect Dis 15 2 (1996) 121-127
27. Govorkova E.A., Kodihalli S., Alymova I.V., Fanget B., and Webster R.G. Growth and immunogenicity of influenza viruses cultivated in Vero or MDCK cells and in embryonated chicken eggs. Dev Biol Stand 98 39-51 (1999) discussion 73-74
28. Potter C.W., and Jennings R. Effect of priming on subsequent response to inactivated influenza vaccine. Vaccine 21 9-10 (2003) 940-945
29. Bizanov G., Janakova L., Knapstad S.E., Karlstad T., Bakke H., Haugen I.L., et al. Immunoglobulin-A antibodies in upper airway secretions may inhibit intranasal influenza virus replication in mice but not protect against clinical illness. Scand J Immunol 61 6 (2005) 503-510
30. Huckriede A., Bungener L., Daemen T., and Wilschut J. Influenza virosomes in vaccine development. Methods Enzymol 373 (2003) 74-91
31. Neutra M.R., Frey A., Kraehenbuhl J.P., and Epithelial. M cells: gateways for mucosal infection and immunization. Cell 86 3 (1996) 345-348
32. Brooking J., Davis S.S., and Illum L. Transport of nanoparticles across the rat nasal mucosa. J Drug Target 9 4 (2001) 267-279
33. Nimmerjahn F., and Ravetch J.V. Fc gamma receptors: old friends and new family members. Immunity 24 1 (2006) 19-28
34. Klaus G.G., Pepys M.B., Kitajima K., and Askonas B.A. Activation of mouse complement by different classes of mouse antibody. Immunology 38 4 (1979) 687-695
35. Heusser C.H., Anderson C.L., and Grey H.M. Receptors for IgG: subclass specificity of receptors on different mouse cell types and the definition of two distinct receptors on a macrophage cell line. J Exp Med 145 5 (1977) 1316-1327
36. Kipps T.J., Parham P., Punt J., and Herzenberg L.A. Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies. J Exp Med 161 1 (1985) 1-17
37. Huleatt J.W., Jacobs A.R., Tang J., Desai P., Kopp E.B., Huang Y., et al. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 25 4 (2007) 763-775
38. Moran T.M., Park H., Fernandez-Sesma A., and Schulman J.L. Th2 responses to inactivated influenza virus can be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection. J Infect Dis 180 3 (1999) 579-585
39. Heil F., Hemmi H., Hochrein H., Ampenberger F., Kirschning C., Akira S., et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303 5663 (2004) 1526-1529
40. Lund J.M., Alexopoulou L., Sato A., Karow M., Adams N.C., Gale N.W., et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci USA 101 15 (2004) 5598-5603
41. Diebold S.S., Kaisho T., Hemmi H., Akira S., and Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303 5663 (2004) 1529-1531
42. Heer A.K., Shamshiev A., Donda A., Uematsu S., Akira S., Kopf M., et al. TLR signaling fine-tunes anti-influenza B cell responses without regulating effector T cell responses. J Immunol 178 4 (2007) 2182-2191
43. Jegerlehner A., Maurer P., Bessa J., Hinton H.J., Kopf M., and Bachmann M.F. TLR9 signaling in B cells determines class switch recombination to IgG2a. J Immunol 178 4 (2007) 2415-2420
44. Ye Z., Liu T., Offringa D.P., McInnis J., and Levandowski R.A. Association of influenza virus matrix protein with ribonucleoproteins. J Virol 73 9 (1999) 7467-7473
45. Heil F., Ahmad-Nejad P., Hemmi H., Hochrein H., Ampenberger F., Gellert T., et al. The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol 33 11 (2003) 2987-2997
46. Lee J., Chuang T.H., Redecke V., She L., Pitha P.M., Carson D.A., et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc Natl Acad Sci USA 100 11 (2003) 6646-6651
47. Joseph A., Louria-Hayon I., Plis-Finarov A., Zeira E., Zakay-Rones Z., Raz E., et al. Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. Vaccine 20 27-28 (2002) 3342-3354
48. Zhang X.Q., Dahle C.E., Weiner G.J., and Salem A.K. A comparative study of the antigen-specific immune response induced by co-delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles. J Pharm Sci 96 12 (2007) 3283-3292
49. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 25 30 (2007) 5467-5484
50. Asahi-Ozaki Y., Yoshikawa T., Iwakura Y., Suzuki Y., Tamura S., Kurata T., et al. Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus. J Med Virol 74 2 (2004) 328-335
51. Asahi Y., Yoshikawa T., Watanabe I., Iwasaki T., Hasegawa H., Sato Y., et al. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines. J Immunol 168 6 (2002) 2930-2938
52. Ichinohe T., Tamura S., Kawaguchi A., Ninomiya A., Imai M., Itamura S., et al. Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J Infect Dis 196 9 (2007) 1313-1320
53. Rimmelzwaan G.F., Fouchier R.A., and Osterhaus A.D. Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr Opin Biotechnol 18 6 (2007) 529-536
54. Geeraedts F., Bungener L., Pool J., ter Veer W., Wilschut J., and Huckriede A. Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs. Influenza and Other Respiratory Viruses 2 2 (2008) 41-51